Displaying drugs 4851 - 4875 of 5280 in total
Alicaforsen
Investigational
SR-123781A
SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Investigational
Albinterferon Alfa-2B
Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human...
Investigational
Matched Description: … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis ... In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they …
Bitolterol
Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Withdrawn
MLN0415
MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these...
Investigational
Spaglumic acid
Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer. Thus it is used in allergic conditions such as allergic conjunctivitis. Specifically spaglumic acid is approved...
Experimental
Pagoclone
Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with...
Investigational
Matched Description: … Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known …
Mozafancogene autotemcel
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition …
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis …
Lomerizine
Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an example being normal-tension glaucoma.
Experimental
Matched Description: … investigated against eye-related diseases that are associated with local circulatory disturbances, an …
Garetosmab
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Matched Description: … to the (normally antagonistic) Activin A led to an interest in Activin A as a therapeutic target. ... [A242297, A242307] The discovery of an activating mutation in the ACVR1 receptor that renders it responsive …
αAβ–Gas6
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic ... It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody …
Arimoclomol
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Matched Description: … Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. …
Lubazodone
Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was discontinued. It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.
Experimental
Matched Description: … Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional …
VTX-801
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
Matched Description: … VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an …
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
Matched Description: … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. …
Formic acid
Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. It is commonly used as a preservative and antibacterial agent in livestock feed.
Experimental
Investigational
Matched Description: … It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom …
SQ-109
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
Matched Description: … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. …
Displaying drugs 4851 - 4875 of 5280 in total